Citi Pharma Ltd. — Interim / Quarterly Report 2026

Apr 30, 2026

==> picture [595 x 350] intentionally omitted <==

CONDENSED INTERIM FINANCIAL STATEMENTS (UN-AUDITED) FOR THE PERIOD ENDED MARCH 31, 2026

CITI PHARMA LIMITED

Email: info@citipharma.com.pk Website: www.citipharma.com.pk

==> picture [82 x 73] intentionally omitted <==

Tel: 042 - 35316587 Address: 588-Q, Johar Town Lahore

==> picture [539 x 32] intentionally omitted <==

TABLE OF CONTENTS

Company Information ------------------------------------------------------------------------------------------3 Director’s Report ------------------------------------------------------------------------------------------------- 4 Director’s Report Urdu-----------------------------------------------------------------------------------------7 Financial Satements--------------------------------------------------------------------------------------------10

COMPANY INFORMATION

2

COMPANY INFORMATION

BOARD OF DIRECTORS

Mr. Nadeem Amjad - Chairman

Mr. Rizwan Ahmad - Chief Executive Officer Dr. Zameer Ul Hassan - Executive Director

Ms. Saira Aslam - Non-Executive Director

Mr. Muhammad Naeem - Non-Executive

Legal Advisors

Mr. Harron Farrukh

Share Registrar

F.D Registrar Services (Pvt) Ltd

Bankers

Director

Mr. Abdul Jaleel Shaikh - Independent Director Ms. Saima Shafi Rana- Independent Director

AUDIT COMMITTEE

Mr. Abdul Jaleel Shaikh (Independent Director) Mr. Nadeem Amjad (Non-Executive Director) Mr. Muhammad Naeem (Non-Executive Director)

Human Resource & Remuneration

Committee

Ms. Saima Shafi Rana (Independent Director) Mr. Zameer Ul Hassan Shah (Executive Director)

Habib Metropolitan Bank Limited Habib Bank Limited - Islamic Pak Brunei Investment Company Limited Samba Bank Limited Soneri Bank Limited Bank of Punjab Limited National Bank of Pakistan Bank Al Habib Limited Meezan Bank Limited Standard Chartered Bank (Pakistan) Limited United Bank Limited

Head Office

588-Q Block, M.A., Johar Town, Lahore Tel: +92-42-35316587

Mr. Rizwan Ahmad (Executive Director)

Management

Chief Financial Officer

Mr. Salman Anwar Malik Company Secretary

Mr. Muhammad Rasheed Alam Head of Internal Auditor

Registered Office

3-KM, Head Balloki Road, Bhai Pheru, Distt Kasur Tel: +92-49-4510189, 4513392

Fax: +92-49-4510191 E-Mail: corporate@citipharma.com.pk Website: www.citipharma.com.pk

Mr. Muhammad Ishaq

External Auditors

Aslam Malik & Co. Chartered Accountants

3

DIRECTORS’ REPORT

The Directors of Citi Pharma Limited (“the Company”) are pleased to present the unaudited condensed interim financial statements for the period ended March 31, 2026. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 ‘Interim Financial Reporting’ and the director’s report is prepared in accordance with section 227 of Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

COMPOSITION OF BOARD

The total number of directors are 7 as the following:

1. Male 5 2. Female 2

Sr. No.	Category	Name
1	Independent Director	1. Mr. Abdul Jaleel Shaikh 2. Ms. Saima Shafi Rana
2	Executive Director	1. Mr. Rizwan Ahmad 2. Mr. Dr. Zameer Ul Hassan Shah
3	Non-Executive Director	1. Mr. Nadeem Amjad 2. Mr. Muhammad Naeem 3. Ms. Saira Aslam

FINANCIAL HIGHLIGHTS

Sales

During the period under review, Citi Pharma Limited delivered a strong financial performance, supported by improved operational efficiencies and sustained demand in the pharmaceutical sector. The Company recorded a turnover of PKR 10,787 million, reflecting a growth of 6.8% compared to PKR 10,100 million in the corresponding period of the previous year.

Profitability

Gross profit registered a significant increase to PKR 1,999 million, showing a 37% rise over PKR 1,456 million in the corresponding period. This improvement was primarily driven by tighter cost controls, an improved product portfolio mix, higher sales contribution from formulation products, and greater operational efficiencies across production processes.

Profit after tax also grew to PKR 883.4 million, a 30% increase as compared to PKR 678.8 million in the corresponding period last year, reflecting continued earnings momentum and the Company’s consistent focus on financial discipline and sustainable profitability.

4

Citi Pharma Limited continues to focus on strengthening its financial position through prudent utilization of growth opportunities, ongoing optimization of operational efficiencies and sustainable value creation for its stakeholders.

FUTURE CHALLENGES & PROSPECTS

The Directors remain cautiously optimistic regarding the future outlook of the pharmaceutical industry, both domestically and internationally. In Pakistan, the sector continues to benefit from rising healthcare expenditure, population growth, increasing disease prevalence, and sustained policy support aimed at strengthening local manufacturing and reducing import dependency. Ongoing regulatory reforms and export promotion initiatives are expected to further support long-term industry growth.

However, the operating environment during the quarter ended 31 March 2026 has remained challenging due to geopolitical tensions, global economic uncertainty, and continued disruptions in supply chains. These factors have resulted in volatility in raw material prices, particularly APIs, higher freight and logistics costs, and extended lead times, thereby impacting industry margins.

Inflationary pressures and exchange rate fluctuations have further increased input costs across the value chain. Key medicines and raw materials, including Paracetamol and other commonly used analgesics and antipyretics, have experienced price increases due to higher import costs and supply constraints. Despite regulated pricing for essential medicines, the gap between rising costs and controlled prices continues to pressure profitability in the sector.

At the same time, the industry continues to benefit from the shift towards value-based healthcare, rising incidence of chronic diseases, and increasing demand for generics and biosimilars. Global supply chain realignments also present export opportunities for compliant manufacturers.

During this phase, Citi Pharma Limited remains focused on disciplined execution of its strategic initiatives, with emphasis on operational efficiency, technological advancement, and sustainable value creation across its business segments.

The Company is currently prioritizing the following initiatives:

• Completion and operationalization of the Biotech formulation, which is expected to enhance product credibility, strengthen regulatory compliance, and facilitate entry into regulated international markets.

• Penicillin Project, this project will further strengthen the Company’s core antibiotic portfolio, enhance backward integration, and improve overall production efficiency and cost competitiveness.

• Development of veterinary formulations (Wholly owned Subsidiary) , with the introduction of products aimed at improving livestock productivity and animal health, thereby diversifying the product portfolio and addressing growing domestic demand. The subsidiary has currently commenced operations through outsourcing of manufacturing activities to third-party facilities, and the Company is in the process of establishing its own dedicated manufacturing plant.

• Strengthening export readiness , including alignment with international regulatory requirements and engagement with potential distributors and strategic partners in selected emerging markets.

In parallel, the Company continues to place strong emphasis on prudent cost control, operational efficiency enhancements, and effective management of working capital to ensure sustained financial resilience in a dynamic and challenging market environment.

5

The Directors also wish to express their sincere appreciation for the continued cooperation and valuable support extended by the Regulatory Authorities, Shareholders, Customers, Vendors, Employees, and all other stakeholders, whose trust and contributions remain integral to the Company’s continued progress.

For and on behalf of the Board

==> picture [100 x 50] intentionally omitted <==

(Rizwan Ahmad) Chief Executive Officer

==> picture [121 x 54] intentionally omitted <==

(Nadeem Amjad) Director

Lahore Dated: April 29, 2026

6

==> picture [476 x 571] intentionally omitted <==

7

==> picture [470 x 568] intentionally omitted <==

8

==> picture [472 x 539] intentionally omitted <==

9

CITI PHARMA LIMITED

CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31,2026

CITI PHARMA LIMITED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31,2026
Note EQUITY AND LIABILTIES SHARE CAPITAL AND RESERVES Authorized Capital: 300,000,000 Ordinary shares of Rs. 10/ each Share Capital and Reserves: 228,461,200 ( June 2025: 228,461,200 ) Ordinary Shares Of Rs. 10/ Each 4 Share Premium Revenue Reserves-Unappropriated Profits Revaluation Surplus On Land NON-CURRENT LIABILITIES Long Term Financing - Secured 5 Deferred Liabilities Lease Liabilities CURRENT LIABILITIES Trade and Other Payables Due to Related Parties Short Term Borrowings-Secured Current Portion of Long Term Liabilities-Secured Dividend Payable Accrued Mark Up Provision For Taxation Contingencies and Commitments 6 TOTAL EQUITY AND LIABILITIES ASSETS NON CURRENT ASSETS Property, Plant and Equipment 7 Long Term Security Deposits Long Term Advance CURRENT ASSETS Stock in Trade Trade Debts- Unsecured Advances Deposits, Prepayments and Other Receivables Short Term Investments Cash And Bank Balances TOTAL ASSETS	March 31, 2026 June 30 , 2025 (Un-audited) (Audited) ------------------Rupees------------------
	3,000,000,000 3,000,000,000
	2,284,612,000 1,391,532,000 1,890,643,407 5,384,617,300	2,284,612,000 1,391,532,000 1,806,817,381 5,384,617,300
	10,951,404,707 10,867,578,681
	30,714,500 208,734,107 53,207,092	- 201,763,862 64,864,123
	292,655,700 266,627,986
	3,598,797,887 - 3,419,760,128 62,186,419 2,502,154 86,081,710 464,125,013	3,858,531,251 5,686,383 2,863,211,696 15,802,536 4,065,868 38,268,523 519,677,557
	7,633,453,313 7,305,243,814 - -
	18,877,513,719 18,439,450,481
	8,624,089,332 27,793,117 254,540,900	8,687,898,852 25,443,117 254,540,900
	8,906,423,349 8,967,882,869
	4,406,558,998 4,217,486,908 1,022,856,402 3,121,000 321,067,061	3,929,701,530 3,078,215,648 903,708,936 956,388,685 603,552,814
	9,971,090,370 9,471,567,612
	18,877,513,719 18,439,450,481

The annexed notes form an integral part of these condensed interim financial statements.

==> picture [97 x 62] intentionally omitted <==

Chief Executive Officer

==> picture [117 x 48] intentionally omitted <==

==> picture [91 x 51] intentionally omitted <==

Director

Chief Financial Officer

10

CITI PHARMA LIMITED

CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED) FOR THE PERIOD AND QUARTER ENDED MARCH 31, 2026

March 31, 2026 March 31, 2025 March 31, 2026 March 31, 2025 Notes Sales- Net 3,084,746,120 3,341,107,922 10,787,560,091 10,100,185,059 Cost of Sales (2,562,119,133) (2,852,435,507) (8,788,404,932) (8,643,865,934) Gross Profit 522,626,987 488,672,415 1,999,155,159 1,456,319,125 Administrative Expenses 54,105,916 57,257,879 165,952,038 161,904,092 Selling Expenses 60,554,025 35,876,526 178,443,759 119,703,970 (114,659,941) (93,134,405) (344,395,797) (281,608,062) Operating Profit 407,967,047 395,538,010 1,654,759,363 1,174,711,063 Financial (Cost) /Income (80,020,639) (99,063,295) (282,036,717) (231,505,104) 327,946,408 296,474,715 1,372,722,646 943,205,959 Other Income/(Loss) 8 22,551,828 23,173,268 79,345,127 165,818,206 350,498,235 319,647,983 1,452,067,772 1,109,024,165 Other Expenses (24,053,800) (25,431,096) (99,651,710) (80,335,099) Profit before income taxes and final tax 326,444,435 294,216,887 1,352,416,062 1,028,689,066 Taxation - Final taxes - - - (4,004) Profit before income tax 326,444,435 294,216,887 1,352,416,062 1,028,685,062 Taxation - Income tax (51,029,268) (73,841,712) (468,975,837) (349,842,286) Profit after income tax 275,415,168 220,375,175 883,440,226 678,842,776 Earnings per share (EPS) - Basic and Diluted 1.21 0.96 3.87 2.97 Three month ended Nine Months Ended ---------------------------------------------Rupees---------------------------------------------	March 31, 2026 March 31, 2025 March 31, 2026 March 31, 2025 3,084,746,120 3,341,107,922 10,787,560,091 10,100,185,059 (2,562,119,133) (2,852,435,507) (8,788,404,932) (8,643,865,934) Three month ended Nine Months Ended ---------------------------------------------Rupees---------------------------------------------	March 31, 2026 March 31, 2025 March 31, 2026 March 31, 2025 3,084,746,120 3,341,107,922 10,787,560,091 10,100,185,059 (2,562,119,133) (2,852,435,507) (8,788,404,932) (8,643,865,934) Three month ended Nine Months Ended ---------------------------------------------Rupees---------------------------------------------	March 31, 2026 March 31, 2025 March 31, 2026 March 31, 2025 3,084,746,120 3,341,107,922 10,787,560,091 10,100,185,059 (2,562,119,133) (2,852,435,507) (8,788,404,932) (8,643,865,934) Three month ended Nine Months Ended ---------------------------------------------Rupees---------------------------------------------	March 31, 2026 March 31, 2025 March 31, 2026 March 31, 2025 3,084,746,120 3,341,107,922 10,787,560,091 10,100,185,059 (2,562,119,133) (2,852,435,507) (8,788,404,932) (8,643,865,934) Three month ended Nine Months Ended ---------------------------------------------Rupees---------------------------------------------
	522,626,987 488,672,415 1,999,155,159 1,456,319,125
	54,105,916 60,554,025	57,257,879 35,876,526	165,952,038 178,443,759	161,904,092 119,703,970
	(114,659,941) (93,134,405) (344,395,797) (281,608,062) 407,967,047 395,538,010 1,654,759,363 1,174,711,063
	(80,020,639) (99,063,295) (282,036,717) (231,505,104)
	327,946,408 296,474,715 1,372,722,646 943,205,959 22,551,828 23,173,268 79,345,127 165,818,206
	350,498,235 319,647,983 1,452,067,772 1,109,024,165 (24,053,800) (25,431,096) (99,651,710) (80,335,099)
	326,444,435 294,216,887 1,352,416,062 1,028,685,062 (51,029,268) (73,841,712) (468,975,837) (349,842,286)
	275,415,168 220,375,175 883,440,226 678,842,776
	1.21 0.96 3.87 2.97

The annexed notes form an integral part of these condensed interim financial statements.

==> picture [88 x 55] intentionally omitted <==

Chief Executive Officer

==> picture [105 x 43] intentionally omitted <==

Chief Financial Officer

==> picture [82 x 46] intentionally omitted <==

Director

11

==> picture [99 x 11] intentionally omitted <==

==> picture [341 x 11] intentionally omitted <==

==> picture [243 x 11] intentionally omitted <==

==> picture [26 x 11] intentionally omitted <==

==> picture [88 x 11] intentionally omitted <==

==> picture [67 x 11] intentionally omitted <==

==> picture [67 x 11] intentionally omitted <==

==> picture [87 x 11] intentionally omitted <==

==> picture [67 x 11] intentionally omitted <==

==> picture [67 x 11] intentionally omitted <==

==> picture [298 x 11] intentionally omitted <==

==> picture [81 x 124] intentionally omitted <==

==> picture [91 x 11] intentionally omitted <==

==> picture [175 x 11] intentionally omitted <==

==> picture [203 x 12] intentionally omitted <==

==> picture [75 x 12] intentionally omitted <==

==> picture [117 x 12] intentionally omitted <==

==> picture [190 x 11] intentionally omitted <==

==> picture [75 x 124] intentionally omitted <==

==> picture [27 x 11] intentionally omitted <==

==> picture [48 x 11] intentionally omitted <==

==> picture [58 x 11] intentionally omitted <==

==> picture [58 x 12] intentionally omitted <==

==> picture [23 x 11] intentionally omitted <==

==> picture [53 x 11] intentionally omitted <==

==> picture [23 x 11] intentionally omitted <==

==> picture [50 x 11] intentionally omitted <==

==> picture [53 x 11] intentionally omitted <==

==> picture [53 x 12] intentionally omitted <==

==> picture [17 x 11] intentionally omitted <==

==> picture [54 x 11] intentionally omitted <==

==> picture [353 x 12] intentionally omitted <==

==> picture [84 x 52] intentionally omitted <==

==> picture [103 x 11] intentionally omitted <==

==> picture [101 x 41] intentionally omitted <==

==> picture [100 x 11] intentionally omitted <==

==> picture [78 x 43] intentionally omitted <==

==> picture [40 x 11] intentionally omitted <==

12

CITI PHARMA LIMITED

STATEMENT OF CHANGES IN EQUITY (UN-AUDITED) FOR THE PERIOD AND QUARTER ENDED MARCH 31, 2026

CITI PHARMA LIMITED STATEMENT OF CHANGES IN EQUITY (UN-AUDITED) FOR THE PERIOD ANDQUARTER ENDED MARCH 31, 2026
			CAPITAL RESERVES		REVENUE RESERVES
PARTICULARS	SHARE CAPITAL	SHARE DEPOSIT MONEY	REVALUATION SURPLUS	SHARE PREMIUM	UN- APPROPRIATED PROFIT	TOTAL
Balance as at July 01, 2024 Total Comprehensive Income for the nine months Final Dividend Paid for the year ended June 2024 @ 32.5% Profit for the period Other comprehensive income Balance as at March 31, 2025 Total Comprehensive Income for the nine months Balance as at July 01, 2025 Final Dividend Paid for the year ended June 2025 @ 35% Profit for the period Other comprehensive income Balance as at March 31, 2026	2,284,612,000 - 309,294,525 1,391,532,000 1,647,690,917 5,633,129,442 - - - - - - - - - - - - - - - - - - - - - Rupees - - - - - - - - - - - - - - - - - - - - - - -
	- -	- -	- -	- -	(742,498,900) 678,842,776 -	(742,498,900) 678,842,776 -
	2,284,612,000 - 309,294,525 1,391,532,000 1,584,034,793 5,569,473,318
	2,284,612,000 - 5,384,617,300 1,391,532,000 1,806,817,381 10,867,578,681 - - (799,614,200) (799,614,200) - - 883,440,226 883,440,226 - -
	2,284,612,000 - 5,384,617,300 1,391,532,000 1,890,643,407 10,951,404,707

The annexed notes form an integral part of these condensed interim financial statements.

==> picture [66 x 41] intentionally omitted <==

Chief Executive Officer

==> picture [80 x 32] intentionally omitted <==

Chief Financial Officer

==> picture [62 x 35] intentionally omitted <==

Director

13

CITI PHARMA LIMITED STATEMENT OF CASH FLOWS (UN-AUDITED) FOR THE PERIOD AND QUARTER ENDED MARCH 31, 2026

CITI PHARMA LIMITED STATEMENT OF CASH FLOWS (UN-AUDITED) FOR THE PERIOD AND QUARTER ENDED MARCH 31, 2026
CASH FLOW FROM OPEARTING ACTIVITIES Profit Before Taxation for the period Adjustments For Non- Cash Items And Other Line Items: Depreciation Financial Charges Accrued Interest Income Unrealized Gain/Loss on Investment in Shares Amortization and Extinguishment of Deferred Grant Worker's Profit Participation Fund Worker's Welfare Fund Profit/ (Loss) before working capital changes Effect of working capital changes Advances, Deposits And Prepayments Trade Debts Stock In Trade Trade And Other Payables Financial Charges Paid Income Tax Paid Gratuity Paid Worker's Profit Participation Fund Net cash flow from operating activities A CASH FLOW FROM INVESTING ACTIVITIES Purchase Of Property, Plant & Equipment Paid for Capital Work in Progress Paid for Long Term Security Deposits Short Term Investments Net cash flow from investing activities B CASH FLOW FROM FINANCING ACTIVITIES Long-term loans obtained/(repaid) Due to Related Parties Lease Rentals Paid Dividend Paid Short Term Borrowings Net Cash flow From Investing Activities C Net Increase/ (decrease) in cash and cash equivalents A+B+C Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Cash and cash equivalents compromise of: Cash in hand Cash at banks Short Term Investments	March 31, 2026 March 31, 2025 1,352,416,062 1,028,689,066 ------------------Rupees------------------
	137,575,042 282,036,717 - - - 72,603,389 27,048,321	119,267,634 231,505,104 (7,510,295) 4,536,958 (582,494) 55,224,360 20,573,781
	519,263,469 423,015,049
	1,871,679,532 1,451,704,115
	(92,107,590) (1,139,271,260) (476,857,469) (286,773,649)	52,129,049 (1,341,546,778) (895,721,955) 888,640,295
	(1,995,009,968) (1,296,499,389)
	(234,223,529) (542,628,334) - (72,611,424)	(262,603,897) (426,353,670) - (68,780,302)
	(849,463,286) (757,737,870)
	(972,793,723) (602,533,144)
	(49,975,885) (23,789,638) (2,350,000) 63,378,575	(45,519,385) (127,563,025) (8,768,141) 19,815,262
	(12,736,948) (162,035,289)
	77,429,000 (5,686,383) (11,987,647) (801,177,914) 556,548,432	(12,859,000) (40,148,000) (8,727,657) (741,386,647) 1,516,732,035
	(184,874,512) 713,610,732
	(1,170,405,183) (50,957,701) 1,491,472,244 1,278,333,631
	321,067,061 1,227,375,930
	9,757,564 2,601,846 311,309,497 28,119,815 - 1,196,654,269
	321,067,061 1,227,375,930

The annexed notes form an integral part of these condensed interim financial statements.

==> picture [76 x 47] intentionally omitted <==

==> picture [91 x 37] intentionally omitted <==

==> picture [71 x 39] intentionally omitted <==

Chief Executive Officer

Chief Financial Officer

Director

14

CITI PHARMA LIMITED CONDENSED INTERIM NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD AND QUARTER ENDED MARCH 31, 2026 Notes 4 SHARES CAPITAL Authorized share capital 300,000,000 Ordinary shares of Rs. 10/ each Issued, subscribed and paid up capital 117,692,000 (June 2025: 117,692,000) Ordinary shares of Rs. 10 each, fully paid in cash 110,769,200 (June 2025: 110,769,200) Ordinary Share of Rs. 10 each issued as fully paid Bonus shares 5 LONG TERM FINANCING - SECURED Term finance against purchase of machinery from Bank Al-Habib Limited Finance of Machinery in SBP (TERF) from Bank Al-Habib Limited Current Portion shown under current liabilities 6 CONTINGENCIES AND COMMITMENTS There has been no material change in the status of contingencies and commitments disclosed in note 15 to the Company's financial statements for the	March 31, 2026 (Un-audited) ------------------Rup	June 30, 2025 (Audited) ees------------------
	3,000,000,000	3,000,000,000
	1,176,920,000 1,107,692,000	1,176,920,000 1,107,692,000
	2,284,612,000	2,284,612,000
	64,000,000 13,429,000	-
	77,429,000 (46,714,500)	- -
	30,714,500	-
	year ended June 30, 20	25.

7 PROPERTY PLANT & EQUIPMENT Operating Fixed Assets Right of Use Assets Capital Work-in-Progress 8 OTHER INCOME Bank Profits on Saving Accounts Profits on Term Deposit Receipts (TDRs) Dividend Income Markup on Investment in Yaqeen Developers Limited (Related Party) Realized Gain on Investment in Shares- Net Insurance Claim Income from non-financial assets Amortisation of Grant Income	8,469,240,584 8,542,377,585 81,952,221 96,414,377 72,896,528 49,106,889 8,624,089,332 8,687,898,852 March 31, 2026 March 31, 2025 1,323,114 1,495,852 53,324,571 112,703,017 - 26,693 24,697,441 34,683,115 - 16,327,034 - - - 582,494 79,345,127 165,818,206 ------------------Rupees------------------

9 TRANSACTION WITH RELATED PARTIES The Related parties comprise principal shareholders and their affiliates, directors, companies with common directorship and key management personnel. The transactions with related parties have been carried out at arms length basis. Detail of transactions and balances at period end with related parties, other than those which have been disclosed elsewhere in these condensed interim financial statements, are as follows:

	79,345,127 165,818,206 TRANSACTION WITH RELATED PARTIES
	The Related parties comprise principal shareholders and their affiliates, directors, companies with common directorship and key management personnel. The transactions with related parties have been carried out at arms length basis. Detail of transactions and balances at period end with related parties, other than those which have been disclosed elsewhere in these condensed interim financial statements,are as follows:
9.1	March 31, 2026 June 30, 2025 Rupees Rupees Nature / name of related party and basis of relationship % of Shareholding Nature of Transactions
	Associated Companies Associated Companies Citi Technologies (Pvt) Ltd. Funds Received-Net - 44,585,244 (Common Directorship) Funds Paid-Net Payments on behalf of the Company Yaqeen Developers Ltd. Markup Income 24,697,441 44,347,388 (Common Directorship) Funds Received - 53,000,000 Citi Innovations (Pvt) Ltd. Funds Received 5,686,383 11,215,933 (Common Directorship) Funds Paid-Net 5,500,000 Payments on behalf of the Company -
	Directors Mr. Rizwan Ahmad Loan obtained (Directorship / CEO) Loan repaid - 31,220,000 Mr. Nadeem Amjad Loan obtained (Directorship / Chairman) Loan repaid - 12,200,000 22.7% 26.0%

REMUNERATION OF CHIEF EXECUTIVES, DIRECTORS AND EXECUTIVES

REMUNERATION OF CHIEF EXECUTIVES, DIRECTORS AND EXECUTIVES
	2026
	Chief Executive	Directors	Executives	Total
Managerial remuneration Bonuses Meeting Fees(Independent directors 2)	8,600,000 -	10,063,280 - 1,450,000	41,214,826 - -	59,878,106 - 1,450,000
No. of persons	1	2	25	28

15

2025	2025	2025	2025	2025	2025
Chief Executive		Directors	Executives		Total
Managerial remuneration Bonuses Meeting Fees(Independent directors 2)	6,600,000 -	10,063,280 - 1,110,000	37,468,024 -		54,131,304 - 1,110,000
No. of persons	1	2	23		26

10 UTILIZATION OF PROCEEDS FROM INITIAL PUBLIC OFFERING

The principal purpose of the issue was to increase the capacity in both segment of Active Pharmaceutical Ingredients (API) and Formulation and to set up a state of the art, 200 bed hospital facility.

Estimated break-up of utilization of the IPO proceeds is mentioned below:

Description	Funds Required (Rupees)	Allocation (%)	Actual Expenditure (Rupees)		Excess/ (Less) Incurred (Rupees)
API Segment Procurement of Plant and Machinery Civil Works	150,000,000 405,194,500	7.4% 19.9%	150,000,000 405,194,500		- -
	555,194,500	27.3% 555,194,500 -
Formulation Segment Civil Works Procurement of Plant and Machinery	250,000,000 307,630,000	12.3% 15.1%	250,000,000 307,630,000		- -
	557,630,000	27.4% 557,630,000 -
Utilization of Excess Proceeds Repayment of Borrowings Working Capital Requirement IPO Expenses	54,197,497 108,902,639 127,667,864	19% 37% 44%	54,197,497 108,902,639 127,667,864		- - -
	290,768,000	100% 290,768,000		-

10.1 In accordance with Section 16A of the Public Offering Regulations, 2017, which requires offering an exit opportunity in the event of a change in the principal purpose of issue as disclosed in the prospectus, the Company, in its Extra Ordinary General Meeting (EOGM) held on 26 June 2025, approved the reallocation of unutilized IPO proceeds. amounting to Rs. 922.5 million originally earmarked for the hospital facility.

The Company has duly complied with the requirements of the IPO Regulations, including:

*Preparation and disclosure of the statement of facts setting out the reasons and rationale for the proposed reallocation; and

*Provision of the required exit opportunity to dissenting shareholders in accordance with applicable laws and regulations

Biotech Formulation - (Ampoules) Reallocation of IPO Funds in light of public offering regulations 2017 section 16A Carbapenem Formulation - (3-Sections) Penicillin Formulation - (4-Sections)	339,114,648 238,651,538 344,785,314	16.7% 11.7% 16.9%			339,114,648 238,651,538 344,785,314
922,551,500 45.3% 922,551,500

11 DATE OF AUTHORIZATION FOR ISSUE

These condensed interim financial statements were authorized for issue on April 29, 2026 by the board of directors of the company.

12 GENERAL

The figures have been rounded off to the nearest rupees.

Corresponding figures have been rearranged, and reclassified, where necessary, for better presentation and disclosure.

==> picture [57 x 36] intentionally omitted <==

==> picture [57 x 5] intentionally omitted <==

----- Start of picture text -----

Chief Executive Officer
----- End of picture text -----

==> picture [68 x 28] intentionally omitted <==

Chief Financial Officer

==> picture [53 x 30] intentionally omitted <==

Director

16